Polyclonal Antibody Therapeutics: Analytical Innovations and Regulatory Perspectives for Addressing Heterogeneity Challenges

TL;DR

This paper discusses how new analytical tools and updated regulations can help overcome challenges in using polyclonal antibodies for therapies.

Contribution

The paper introduces recent analytical innovations and regulatory insights to better characterize and standardize polyclonal antibody therapeutics.

Findings

High-resolution analytical methods improve the characterization of polyclonal antibody quality attributes.

Regulatory frameworks are evolving to support standardized criteria for pAb-based therapeutics.

New technologies enable detailed evaluation of structural and functional properties of pAbs.

Abstract

Polyclonal antibodies (pAbs) are a cornerstone of the
adaptive
immune system, providing broad-spectrum protection by recognizing
and neutralizing diverse antigens. Intravenous immunoglobulins (IVIg)
derived from animal/human plasma are widely used to treat diseases
such as primary immunodeficiencies, autoimmune neurological disorders,
and situations requiring rapid immune protection, such as emerging
infectious disease outbreaks. Compared with monoclonal antibodies
(mAbs), pAbs offer several advantages, including faster, less technically
demanding, and more cost-effective production, often directly from
immunized animals or human serum. However, their complex, heterogeneous
naturereflecting the polyclonal response to multiple epitopescreates
significant challenges for characterization, quality control, and
regulatory approval. pAbs have been underutilized in therapeutic applications
due to the absence of robust, standardized analytical tools capable
of fully assessing their heterogeneity. Conventional chromatographic
and spectroscopic methods yield limited qualitative and quantitative
information, insufficient for detailed structural and functional evaluation.
This perspective highlights recent advances in high-resolution analytical
technologies, particularly chromatographic and mass spectrometric
approaches, that enable in-depth characterization of critical quality
attributes (CQAs) of pAbs. These analytical strategies facilitate
the assessment of parameters such as structural integrity, molecular
size distribution, subclass composition, and polyclonality, which
are crucial for ensuring product quality. Alongside these technical
developments, regulatory frameworks for pAb-based therapeutics are
evolving, emphasizing the need for standardized analytical criteria
to ensure safety, efficacy, and batch-to-batch consistency. In our
view, by integrating new analytical capabilities with clear regulatory
expectations, pAbs can be more effectively developed as therapeutic
agents, complementing mAbs and expanding the range of immunoglobulin-based
interventions in clinical practice.

Figures